ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Network pharmacology and experimental verification-based strategy for exploring the mechanisms of luteolin in the treatment of osteosarcoma

Huang, Renxuan; Xu, Mingxian; Guo, Weitang; Cheng, Mingzhe; Dong, Rui; Tu, Jian; Xu, Shao*; Zou, Changye*广东省人民医院; 广东省心血管病研究所; 南方医科大学; 中山大学; 1
Cancer Cell International2023-9-25DOI: 10.1186/s12935-023-03046-x
1被引8阅读
引用收藏
分享

摘要

BackgroundLuteolin is an active ingredient in various traditional Chinese medicines for the treatment of multiple tumors. However, the mechanisms of its inhibitory effect on osteosarcoma proliferation and metastasis remain unclear.PurposeTo elucidate the anti-osteosarcoma mechanisms of luteolin based on network pharmacology and experimental verification.Study DesignIntegrate network pharmacology predictions, scRNA-seq analysis, molecular docking, and experimental validation.MethodsLuteolin-related targets and osteosarcoma-associated targets were collected from several public databases. The luteolin against osteosarcoma targets were screened and a PPI network was constructed to identify the hub targets. The GO and KEGG enrichment of osteosarcoma-associated targets and luteolin against osteosarcoma targets were performed. And scRNA-seq analysis was performed to determine the distribution of the core target expression in OS tissues. Molecular docking, cell biological assays, and osteosarcoma orthotopic mouse model was performed to validate the inhibitory effect and mechanisms of luteolin on osteosarcoma proliferation and metastasis.ResultsNetwork pharmacology showed that 251 luteolin against osteosarcoma targets and 8 hub targets including AKT1, ALB, CASP3, IL6, JUN, STAT3, TNF, and VEGFA, and the PI3K-AKT signaling pathway might play an important role in anti-osteosarcoma of luteolin. Analysis of public data revealed that AKT1, IL6, JUN, STAT3, TNF, and VEGFA expression in OS tissue was significantly higher than that in normal bones, and the diagnostic value of VEGFA for overall survival and metastasis was increased over time. scRNA-seq analysis revealed significantly higher expression of AKT1, STAT3, and VEGFA in MYC+ osteoblastic OS cells, especially in primary samples. Moreover, the docking activity between luteolin and the hub targets was excellent, as verified by molecular docking. Experimental results showed that luteolin could inhibit cell viability and significantly decrease the expression of AKT1, STAT3, IL6, TNF, and VEGFA, and luteolin could also inhibit osteosarcoma proliferation and metastasis in osteosarcoma orthotopic mouse model.ConclusionThis study shows that luteolin may regulate multiple signaling pathways by targeting various genes like AKT1, STAT3, IL6, TNF, and VEGFA to inhibit osteosarcoma proliferation and metastasis.

学科与关键词

关键词
LuteolinNetwork pharmacologyOsteosarcomaMolecular dockingscRNA-seqOrthotopic mouse model
相关
加载中…
  • Mechanism and Experimental Verification of Luteolin for the Treatment of Osteoporosis Based on Network Pharmacology
    Liang, Guihong; Zhao, Jinlong; Dou, Yaoxing; Yang, Yuan; Zhao, Di; Zhou, Zhanpeng; Zhang, Rui; Yang, Weiyi*; Zeng, Lingfeng*Frontiers in Endocrinology, 2022, 13: 866641.被引 9
  • Use of network pharmacology and molecular docking to explore the mechanism of action of curcuma in the treatment of osteosarcoma
    Hu, Minhua; Yan, Hongsong; Li, Haishan; Feng, Yuanlan; Sun, Weipeng; Ren, Yueyi; Ma, Luyao; Zeng, Wenxing; Huang, Feng; Jiang, Ziwei*; Dong, Hang*Scientific Reports, 2023, 13(1): 9569.被引 2
  • Network Pharmacology Prediction: The Possible Mechanisms of Cinobufotalin against Osteosarcoma
    Chen, Riyu; Guan, Zeyi; Zhong, Xianxing; Zhang, Wenzheng*; Zhang, Ya*Computational and Mathematical Methods in Medicine, 2022, 2022: 3197402.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Cell International
发表日期
2023-09-25
卷期
第 23 卷, 第 1 期
页码
213
DOI
10.1186/s12935-023-03046-x
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81972507, 82273413]

作者

  • H

    Huang, Renxuan (第一作者)

    1 · 2 · sun yat sen univ

  • X

    Xu, Mingxian

    1 · 2 · sun yat sen univ

查看全部 8 位作者收起作者
  • G

    Guo, Weitang

    1 · 2 · sun yat sen univ

  • C

    Cheng, Mingzhe

    1 · 2 · sun yat sen univ

  • D

    Dong, Rui

    guangdong cardiovasc inst · guangdong prov peoples hosp · southern med univ

  • T

    Tu, Jian

    1 · 2 · sun yat sen univ

  • X

    Xu, Shao (通讯)

    southern med univ

  • Z

    Zou, Changye (通讯)

    1 · 2 · sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417